- Conditions
- Nasal Polyposis
- Interventions
- AK001 low dose, AK001 high dose, Placebo
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nasal Polyposis
- Interventions
- Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 37 more
- Conditions
- Aspirin Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma, Nasal Polyps
- Interventions
- Not listed
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
- Biological · Other · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
- Conditions
- Chronic Sinusitis, Rhinosinusitis, Nasal Polyps
- Interventions
- Prednisone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Sinusitis, Nasal Polyposis
- Interventions
- S8 Sinus Implant, Mometasone furoate nasal spray, Sham
- Drug · Procedure
- Lead sponsor
- Intersect ENT
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Irvine, California • Sacramento, California + 33 more
- Conditions
- Sinusitis, Nasal Polyps
- Interventions
- Verapamil HCl, Placebo
- Drug · Other
- Lead sponsor
- Benjamin Bleier
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Size of Nasal Polyps, Control of Symptoms
- Interventions
- Not listed
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 17 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
- Interventions
- PF-06817024, Placebo for PF-06817024
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Fresno, California • Huntington Beach, California + 16 more
- Conditions
- Nasal Polyps, Chronic Rhinosinusitis
- Interventions
- Omalizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Roseville, California • Miami, Florida + 8 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- OPN-375, Placebo
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
- Conditions
- Chronic Rhinosinusitis
- Interventions
- Etokimab, Placebo, Mometasone Furoate Nasal Spray
- Biological · Drug
- Lead sponsor
- AnaptysBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Canoga Park, California • Roseville, California + 24 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- lunsekimig, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- La Jolla, California • Roseville, California • San Diego, California + 11 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps
- Interventions
- Prednisone, Topical mometasone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Sinusitis With or Without Nasal Polyps
- Interventions
- Fluticasone Propionate
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Colorado Springs, Colorado • Largo, Florida + 15 more
- Conditions
- Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
- Interventions
- Dupilumab SAR231893, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Roseville, California • Stockton, California • Denver, Colorado + 7 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Itepekimab (SAR440340), Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- La Mesa, California • Oklahoma City, Oklahoma
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps, Asthma
- Interventions
- Dupilumab, Omalizumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- Lunsekimig, Mometasone furoate nasal spray (MFNS)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 9
- States / cities
- La Jolla, California • Roseville, California • Boise, Idaho + 6 more
- Conditions
- ASA Triad, Asthma, Nasal Polyps, And Aspirin Intolerance
- Interventions
- Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Nasal Polyps
- Interventions
- Fluticasone Propionate
- Drug
- Lead sponsor
- Optinose US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Brandon, Florida • Normal, Illinois + 13 more
- Conditions
- Polyp of Nasal Sinus
- Interventions
- Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Rhinosinusitis (Diagnosis), Asthma, Nasal Polyps
- Interventions
- Reslizumab
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, New York